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Abstract: Colorectal cancer is currently the third deadliest cancer in the United States and will claim an estimated 
49,190 U.S. lives in 2016. The purpose of this review is to summarize our current understanding of this disease, 
based on nationally published statistics and information presented in peer-reviewed journal articles. Specifically, 
this review will cover the following topics: descriptive epidemiology (including time and disease trends both in the 
United States and abroad), risk factors (environmental, genetic, and gene-environment interactions), screening, 
prevention and control, and treatment. Landmark discoveries in colorectal cancer risk factor research will also be 
presented. Based on the information reviewed for this report, we suggest that future U.S. public health efforts aim 
to increase colorectal cancer screening among African American communities, and that future worldwide colorectal 
cancer epidemiology studies should focus on researching nutrient-gene interactions towards the goal of improving 
personalized treatment and prevention strategies.
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Introduction
The term colorectal cancer refers to a slowly 
developing cancer that begins as a tumor or tis-
sue growth on the inner lining of the rectum or 
colon [1]. If this abnormal growth, known as a 
polyp, eventually becomes cancerous, it can 
form a tumor on the wall of the rectum or colon, 
and subsequently grow into blood vessels or 
lymph vessels, increasing the chance of metas-
tasis to other anatomical sites [1, 2]. Of the 
cancers that begin in the colorectal region, the 
vast majority (over 95%) are classified as ade-
nocarcinomas [1]. These begin in the mucus-
making glands lining the colon and rectum [1, 
3]. Other less-common cancers of the colorec-
tal region include carcinoid tumors (which begin 
in hormone-producing intestinal cells), gastro-
intestinal stromal tumors (which form in spe-
cialized colonic cells known as interstitial cells 
of Cajal), lymphomas (immune system cancers 
that form in the colon or rectum), and sarcomas 
(which typically begin in blood vessels but occa-
sionally form in colorectal walls) [1, 3].
Descriptive epidemiology
In the United States, colorectal cancer is the 
third deadliest of all cancers. In 2016 there will 
be an estimated 134,490 new colorectal can-
cer cases (70,820 in males and 63,670 in 
females) along with 49,190 colorectal cancer 
deaths (26,020 and 23,170 in males and 
females, respectively). Colorectal cancer ranks 
third, only behind prostate cancer and lung can-
cer, for new cases in males (8% of all new can-
cer cases), and behind breast cancer and lung 
cancer for new cases in females (8% of all new 
cancer cases). Similarly, only lung cancer and 
prostate cancer are expected to claim more 
U.S. male lives than colorectal cancer in 2016, 
and only lung cancer and breast cancer are 
expected to take more U.S. female lives (8% of 
total cancer deaths for both genders) [4]. Thus 
colorectal cancer remains a heavy burden on 
the United States population, as 1,177,556 
U.S. residents were estimated to have been liv-
ing with colorectal cancer in 2013 [5].
Over the last several decades, however, the 
U.S. burden of colorectal cancer has been 
decreasing. National statistics have revealed 
reductions in both incidence rates and death 
rates, while 5-year survival rates have also 
steadily improved. Between 1975 and 2012, 
the age-adjusted death rate for colorectal can-
cer in the United States, across all races and 
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both sexes, shrank by half (28.58 deaths per 
100,000 in 1976 to 14.45 deaths per 100,000 
in 2013) [6]. In similar fashion, age-adjusted 
incidence rates in the U.S., across both sexes 
and all races, dropped from the low-to-mid 60s 
per 100,000 in the 1970s and 1980s to 37.20 
new cases per 100,000 in 2013 [7]. Additionally, 
between 1975 and 2011 (again, for all races 
and both sexes in the U.S.) the 5-year survival 
rate rose from a low of 49.8% to a high of 66.2% 
[8].
Public federal databases do an admirable job 
of describing how the burden of colorectal can-
cer in the U.S. has slowly lightened since the 
1970s. However, other published data show 
that this trend is not consistent across all geo-
graphic regions, particularly when considering 
Eastern nations. Although the highest colorec-
tal cancer incidence rates can still be found in 
North America, Europe, and Australia/New 
Zealand, other countries with historically low 
rates are now experiencing increased risk [9]. 
For example, Japan and Thailand are suffering 
rapid increases in colorectal cancer incidence 
[10], and incidence has been steadily increas-
ing in Iran for the past 30 years [11]. The rates 
have more than doubled in Saudi Arabia since 
1994 [12], about the same time that rates 
started to increase in the Philippines [13]. 
Elsewhere in the East, colorectal cancer inci-
dence rates have also been slowly increasing, 
for example, in Jordan [14], as well as China, 
South Korea, and Singapore, all regions where 
cancers of the stomach and liver have typically 
caused the greatest concern [15].
Another observable difference between inci-
dence of colorectal cancer in the East and West 
can be seen in the average age of diagnosis. In 
the United States and European Union, only 
about 2-8% of cases occur in individuals under 
40 years of age [16, 17], whereas Egypt, Saudi 
Arabia, the Philippines, and Iran show rates of 
38%, 21%, 17%, and 15-35%, respectively for 
this same age group [11, 13, 18, 19].
Risk factors
Environmental factors
Many studies have attributed the increased 
risk of developing colorectal cancer to living the 
“Westernized lifestyle” [10, 14-16, 20, 21]. This 
term encompasses obesity, sedentary behav-
ior, and a high-meat, high-calorie, fat-rich, fiber-
deficient diet, and has been linked to increased 
colorectal cancer risk [20, 22]. The landmark 
study that first connected dietary fat to risk of 
colon carcinogenesis took place in 1969, pio-
neered by Ernst Wynder and coworkers. They 
discovered that Japanese individuals of higher 
socioeconomic status (SES) were more likely to 
develop colon cancer than those who were less 
affluent, possibly due to their more Westernized 
diet. It was then first hypothesized that dietary 
fat, through its influence on bacterial flora, has 
an effect on colon cancer pathogenesis [21]. 
Building on this hypothesis, later researchers 
theorized that high-fat diets promote carcino-
genesis by the formation of deoxycholic acid 
and lithocholic acid. High fat intake stimulates 
the production of bile acids from the liver, which 
after contact with anaerobic bacteria in the 
colon, are dehydrogenated to form these com-
pounds [22]. 
Alcohol consumption and tobacco smoking 
also increase risks for colorectal cancer. In 
2007, the International Agency for Research on 
Cancer (IARC) declared that there was suffi-
cient substantiated evidence to infer that alco-
hol is a causal factor for colorectal cancer [23]. 
Research has since revealed that, when com-
pared to non/occasional drinkers, people who 
consume at least 4 drinks per day are at a 52% 
increased risk for developing this disease [23]. 
Mechanistically, this carcinogenic process may 
reflect the impact of alcohol on folate synthe-
sis. Specifically, alcohol entering the colon is 
microbially metabolized into acetaldehyde, 
which degrades folate in vivo [22, 24]. Because 
folate is required for DNA synthesis and repair, 
folate deficiency can lead to chromosome 
breakage, uracil misappropriation, and other 
DNA precursor imbalances, all of which can 
contribute to carcinogenesis [25]. Regarding 
cigarette smoking, research has revealed that 
tobacco smoke significantly increases colorec-
tal cancer incidence and mortality and has 
been associated with a twofold to threefold 
increase in the risk of developing colorectal 
adenoma [26, 27]. This is due to the ability of 
the gastrointestinal tract and circulatory sys-
tem to spread cigarette carcinogens to colorec-
tal mucosa, elevating the risk of inflammation, 
mutagenesis, and carcinogenesis [22].
In addition to the above environmental risk fac-
tors, high blood levels of insulin, gastrointesti-
nal inflammation, and certain meat-cooking 
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methods may also increase risk of colorectal 
carcinogenesis [22]. Hyperinsulinemia increas-
es the risk of colorectal cancer through promo-
tion of colon cell proliferation and reduction of 
apoptosis [28]. Regarding gastrointestinal 
inflammation and colorectal cancer, research 
has also revealed a link between ulcerative 
colitis and colorectal carcinogenesis. Evidence 
suggests that about 1% of all colorectal cancer 
cases are due to the chronic inflammation 
associated with ulcerative colitis, and the risk 
for developing cancer directly correlates to the 
amount of time a patient has endured the 
inflammatory condition [29]. Similarly, Crohn’s 
disease, marked by intestinal inflammation, 
has also been shown to increase the risk of 
colorectal cancer, although not to the same 
degree as ulcerative colitis [22]. Additionally, 
certain methods of cooking meat may also 
increase the risk of developing colorectal can-
cer. Studies have shown that with frying, boil-
ing, charcoal broiling, or other methods in which 
meat is cooked at extremely high temperatures, 
mutagenic heterocyclic amines and polycyclic 
aromatic hydrocarbons can form, leading to the 
production of N-nitroso, a known human car-
cinogen in the colon [22, 30]. These mutagens 
may not be the only cause for concern, as fur-
ther research has suggested that other com-
pounds such as quinoxaline and pyridine can 
also increase risk of colorectal cancer, particu-
larly distal adenomas [31].
However, in direct opposition to all these risk 
factors, several environmental factors actually 
lower the risk of developing colorectal cancer. 
One such protective factor is the ingestion of 
fish and fish oil, which has been shown not only 
to stifle the promotion of colonic tumors, but 
also to reduce the incidence of these tumors 
[32]. In fact, fish consumption can be so power-
ful a protective factor that one study document-
ed evidence of protection against colorectal 
carcinogenesis even in European populations 
that typically consume high amounts of other 
meat and animal fat [33]. 
Another protective factor against colorectal 
cancer is a high intake of dietary fiber. In 1971, 
Denis Burkitt conducted the landmark study 
first linking fiber consumption to protection 
against colorectal cancer. He observed that 
colorectal cancer, as well as other non-infec-
tious bowel diseases, were extremely rare in 
communities that survived on a highly fibrous 
diet, but were common in economically devel-
oped countries where low-fiber diets predomi-
nated [34]. Burkitt then hypothesized that a 
lifestyle devoid of adequate dietary fiber may 
be a causative factor for the increased colorec-
tal cancer incidence seen in economically 
advanced nations, probably due to abnormal 
carcinogenic changes in the bacterial flora [34].
Additional factors documented to afford protec-
tion against colorectal cancer are: a high intake 
of vitamin D, a high calcium intake, habitual 
physical exercise, and the regular usage of 
aspirin. Evidence shows that taking 1000 IU/
day of vitamin D can decrease colorectal can-
cer risk by 50%, and intake of 1250 mg/day of 
calcium can significantly reduce the risk of 
colorectal cancer [35]. Mechanistically, calci-
um provides this protection by decelerating 
colonic epithelium proliferation and by neutral-
izing bile acids [35]. Regarding the benefits of 
physical activity, studies have revealed that 
increasing exercise from before to after diagno-
sis is associated with lower total mortality [36]. 
One such study specifically found that regular 
physical exercise can reduce colorectal cancer 
risk by almost 25% [37]. Another study showed 
that those who used aspirin regularly (at least 
twice per week) had lower risk of colorectal 
cancer than those who used it less often. The 
hypothesized mechanism underlying this effect 
is the ability of aspirin to inhibit cyclooxygen-
ase-2, an enzyme that stimulates the colorectal 
carcinogenic processes of inflammation and 
cell proliferation [38]. 
Genetic factors
In addition to the environmental factors above, 
colorectal cancer also has a significant genetic 
basis. Research in this area has come a long 
way in the last 25-30 years, thanks in part to a 
pioneer in this field, Professor Walter Bodmer. 
In 1987, Professor Bodmer made a landmark 
discovery when he determined that a gene 
called APC, which acts to help prevent cancer 
when functional, greatly increases colorectal 
cancer risk when defective. Bodmer is thus 
credited with saving many lives via genetic test-
ing for faults in this gene, thereby reducing UK 
colorectal cancer deaths by approximately 33% 
[39]. Another scientist, Dr. Bert Vogelstein, 
received awards and recognition for his land-
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mark contributions to colorectal cancer re- 
search. Since the mid 1980s, Dr. Vogelstein 
and coworkers have published crucial findings 
pertaining to colorectal tumorigenesis, docu-
menting how the accrual of genetic changes to 
certain oncogenes and tumor-suppressor 
genes can result in colorectal tumors [40].
Many subsequent discoveries have elucidated 
the role of genetics in both the development 
and the prevention of colorectal cancer. For 
example, research by the UK IBD Genetics 
Consortium and the Wellcome Trust Case 
Control Consortium showed that the HNF4A, 
CHDH1, and LAMB1 genes (on chromosomes 
20q13, 16q22, and 7q31, respectively) are 
linked to colorectal cancer susceptibility. This 
research was also the first to identify a genetic 
link between ulcerative colitis and colorectal 
cancer [41]. Additional research determined 
that the genetic variants miR-196a2, SNP rs60- 
17342, and the C allele of the SNP rs11614913 
also conferred elevated risk of developing 
colorectal cancer [42, 43]. Genes have also 
been shown to affect not only the incidence of 
colorectal cancer, but mortality as well, as the 
rs4939827 SNP located on the SMAD7 gene 
has been linked to shorter patient survival [43].
Conversely, research has also uncovered sev-
eral genetic protective factors. For example, 
one study found that SNP rs4779584 on chro-
mosome 15q13 is associated with a lowered 
risk of colorectal cancer mortality. The same 
study showed that SNP rs10795668 on chro-
mosome 10p14 is linked to lower risk of recur-
rence. Furthermore, this recurrence link per-
tained only to those treated with chemotherapy, 
not those treated otherwise; further, the pro-
tective effect was associated only with the vari-
ant-containing genotype, not the wild genotype 
[44]. Additionally, a recent study identified two 
genetic markers that play a role in colorectal 
cancer risk. One marker, the T allele in rs11- 
676348, is an ulcerative colitis susceptibility 
locus found to be protective against colorectal 
cancer. This locus, located on chromosome 2, 
is only slightly downstream of the CXCR2 gene, 
a gene previously linked to the development of 
colorectal cancer via chronic inflammation. 
This is significant, as rs11676348 was found to 
specifically afford protection against colorectal 
cancer tumors that had a mucinous compo-
nent, were microsatellite instability-high, or 
associated with a Crohn’s-like reaction, all of 
which are indicative of considerable inflamma-
tion [45]. The other marker, rs102275 (a Cr- 
ohn’s disease susceptibility locus on chromo-
some 11), was also found to be inversely relat-
ed to colorectal cancer risk [45]. 
There is also evidence that some genes are 
capable of both risk reduction and protection 
against colorectal cancer, and new research 
suggests that MTHFR is among them. When 
researchers tested for an overall association 
across all populations, the homozygous TT gen-
otype for MTHFR 677 was found to be protec-
tive against colorectal cancer [46]. Subgroup 
analysis, however, did not find these protective 
effects in all populations, as this same MTHFR 
677 TT genotype was found to be a colorectal 
cancer risk factor for those residing in Turkey, 
Romania, Croatia, Hungary, Portugal, Mexico, 
the U.S., Taiwan, India, and Egypt [46]. Consi- 
dering research linking genetics to colorectal 
cancer risk and protection alike, about 35% of 
colorectal cancer cases are influenced by 
genetic factors [43]. 
Effect of gene-environment interactions on 
colorectal cancer
Gene-environment interactions influence colo- 
rectal cancer risk. For example, exercise may 
interact with certain genes to affect colorectal 
cancer outcome. Level of physical activity was 
found to be associated with colorectal cancer 
survival among individuals who were PTGS2-
positive, but no such association was seen 
among those who were PTGS2-negative [47]. 
Similarly, among patients with p27 expression, 
those who were physically active had 68% lower 
colon cancer mortality rates than those who 
were not physically active. However, these exer-
cise benefits were absent in those without p27 
expression [48].
Interactions between genetic factors and envi-
ronmental factors, such as obesity, aspirin, 
alcohol consumption, vitamin D intake, and 
polyunsaturated fatty acids, have also been 
discovered to influence colorectal cancer risk. 
As body mass index (BMI) increases, so does 
the risk of colorectal cancer for individuals who 
are CTNNB1-negative (no such association is 
seen among CTNNB1-positive patients) [49]. 
However, for obese patients (BMI of at least 
30), greater colorectal cancer survival was 
seen in those who were CTNNB1-positive, while 
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among non-obese patients, CTNNB1 status 
had no effect on survival [49].
Regarding aspirin, consistent intake has been 
associated with a lower incidence of colorectal 
cancer for individuals with the wild-type BRAF 
gene, and longer colorectal cancer survival for 
those carrying the mutated PIK3CA gene. Such 
associations were not seen in those with 
mutated BRAF or wild-type PIK3CA genotypes 
[50, 51]. Similarly, consistent aspirin intake 
was also found to decrease colorectal cancer 
risk in patients with high expression of 
15-PGDH, whereas no such relationship was 
found in those with low 15-PGDH expression 
[52]. Also, it has been reported that aspirin 
reduces risk of colorectal cancer, particularly 
tumors with activated CTNNB1, among individ-
uals with rs6983267 GT/TT genotypes but not 
among individuals with GG genotypes [53]. In 
addition, a recent genome-wide gene-environ-
ment interaction study identified that the che-
mopreventive effect of aspirin and other non-
steroidal anti-inflammatory drugs (NSAIDs) on 
colorectal cancer risk differed according to 
genetic variation at two single nucleotide po- 
lymorphisms (SNPs) at chromosomes 12 (rs- 
2965667) and 15 (rs16973225) [54]. Rega- 
rding alcohol consumption, research has deter-
mined that regular alcohol drinkers with low 
IGF2 DMR0 methylation have an increased risk 
of colorectal cancer, but those with higher IGF2 
DMR0 methylation ability have no such elevat-
ed risk [55].
Pertaining to vitamin D, recent research has 
also discovered that individuals with high blood 
25(OH)D levels were less likely to develop 
colorectal cancer if they also had high-level in- 
tratumoral periglandular reaction as opposed 
to lower levels of this reaction [56]. Researchers 
have also revealed an interaction between 
marine ω-3 polyunsaturated fatty acids (PUFAs) 
and colorectal cancer. Those with high PUFA 
consumption are less likely to develop mic- 
rosatellite-high colorectal cancer tumors. The 
risk of microsatellite-stable colorectal cancer 
tumors, however, is not modified by PUFA intake 
[57].
Screening
Screening for colorectal cancer involves testing 
for pre-cancerous colorectal polyps or early-
stage cancer before the manifestation of symp-
toms, before the disease has a chance to grow 
or spread, and while treatment is easier to 
manage, less expensive, and more likely to be 
successful [9, 58]. In the United States, the 
Centers for Disease Control and Prevention 
(CDC) and the U.S. Preventive Services Task 
Force recommend that men and women 
between the ages of 50 and 75 be screened for 
colorectal cancer through high-sensitivity fecal 
occult blood testing (FOBT), sigmoidoscopy, or 
colonoscopy [59]. 
FOBT, recommended annually, tests for colorec-
tal cancer by detecting blood in a patient’s 
stool through the use of a chemical called guai-
ac or antibodies. With this method, the patient 
simply obtains a small sample of stool, places it 
in a test kit, then returns it to their health care 
provider for laboratory analysis. For the sig-
moidoscopy, a physician inserts a thin, flexible 
tube into a patient’s rectum to check for poten-
tially cancerous polyps either in the rectum or 
the lower region of the colon. It is recommend-
ed that this test be performed every five years. 
Similar to the sigmoidoscopy, in a colonoscopy 
the doctor uses a thin, flexible, tube to check 
for polyps or any sign of carcinogenesis. For 
this test, however, a longer tube is used as the 
doctor will examine the rectum and the entire 
colon, possibly removing polyps during the test. 
Patients are recommended to undergo this pro-
cedure every 10 years. Although these are the 
three screening techniques recommended by 
the U.S. Preventive Services Task Force, three 
other screening methods (the double-contrast 
barium enema, the virtual colonoscopy, and the 
stool DNA test) are sometimes used and/or rec-
ommended by other entities [59].
Because of evidence indicating that the risk of 
colorectal pathogenesis and carcinogenesis 
increases exponentially around age 50 [49], it 
is strongly recommended that screening begin 
at age 50 for previously asymptomatic persons 
[59-61]. However, despite these recommenda-
tions and the strong evidence indicating the 
effectiveness, relative safety, and proven re- 
sults of colorectal screening [61, 62], persis-
tent issues keep screening rates low, both in 
the U.S. and abroad. 
One such issue that can be seen in the United 
States lies in the unfortunate confluence of 
elevated risk and lower screening rates among 
the African American population. Compared 
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with Caucasian Americans, African Americans 
present with colorectal cancer at younger ages, 
have higher rates of colorectal cancer preva-
lence across all ages, demonstrate higher pro-
portion of colorectal carcinogenesis prior to 
age 50, are more likely to die from colorectal 
cancer, demonstrate more metastasis-associ-
ated genetic biomarkers, and are less likely to 
engage in screening (56% of African Americans 
over age 50 follow recommended screening 
guidelines, compared to 62% of Caucasians) 
[60, 63]. Many of the aforementioned morbidity 
and mortality statistics can be attributed to this 
community’s poorer nutrition, higher obesity 
rates, and lower rates of physical activity [51]. 
Thus it has been suggested that community-
specific guidelines for this population should 
advocate for the commencement of screening 
prior to age 50 [60].
Another factor contributing to the low rates of 
colorectal cancer screening is the feasibility of 
establishing certain screening procedures in 
developing/lower-resource countries. For exam- 
ple, though a colonoscopy is generally consid-
ered to be a very effective and sensitive screen-
ing option, it requires significant cost, a skilled 
examiner, and extensive procedures, all of 
which may make colonoscopies virtually impos-
sible to implement on a large scale in many 
developing nations [9]. Because of this, the 
FOBT, which is relatively inexpensive, conve-
nient, and easy to administer, is a better option 
for primary colorectal cancer screening in cer-
tain geographic areas; in fact, many countries 
have already established a national screening 
program using the FOBT. Although not as sensi-
tive as a colonoscopy, the FOBT has been 
shown to reduce colorectal cancer mortality by 
one-third, leading to the recommendation that 
this be the test of choice in areas where a more 
structural examination may not be feasible 
and/or possible [64].
Prevention and control
The prevention and/or control of colorectal can-
cer can be multifaceted. As previously men-
tioned, the regular consumption of fish, fiber, 
vitamin D, and calcium, as well as regular exer-
cise and aspirin intake, can all help prevent the 
development of colorectal cancer [32-37]. In 
fact, the combination of dietary change along 
with the intake of anti-inflammatory drugs can 
not only prevent the growth of new polyps, but 
also stunt the growth of existing polyps [65]. In 
addition, family/community interventions can 
also be effective in helping to prevent colorec-
tal cancer [66]. Family-based support for a fam-
ily member with colorectal cancer, through the 
use of motivation and encouragement when 
performing prevention measures such as 
screening, exercising, and adopting a healthy 
diet, can be an effective learning tool to help 
with carcinogenesis prevention [66]. Another 
way this method can aid in prevention is 
through the advice of an older, trusted family 
member. To make this point, an example was 
given of how an individual, uneasy about a 
screening procedure, was calmed by older fam-
ily members who shared their own experiences 
with such procedures [66]. Family-based inter-
ventions such as this, as well as screening, 
genetic testing, and the other aforementioned 
environmental preventive measures, can all 
play effective roles in both the prevention and 
control of colorectal cancer.
Treatment
The choice of treatment for colorectal cancer 
can depend on several factors, including the 
patient’s health, the size of the tumor, and its 
location [65]. Surgery is the most common 
treatment option, and the type of surgery used, 
again, depends on variables such as the loca-
tion of the cancer and the existence and extent 
of metastasis [65, 67]. As mentioned above, if 
cancer is found only in a single polyp, it can be 
removed during a colonoscopy [59, 65]. 
However, if the cancer has affected a larger 
area, then a bowel resection may be necessary 
[65]. Resection may include the partial or total 
removal of the colon as well as other adjacent 
organs (such as stomach or abdominal wall) 
[65]. 
When surgery is not necessary, treatment can 
include radiofrequency ablation, cryosurgery, 
chemotherapy, radiation therapy, or targeted 
therapy. Radiofrequency ablation involves the 
use of electrodes, inserted either directly 
through the skin or through an abdominal inci-
sion, to kill cancer cells. In cryosurgery, freezing 
techniques are used to destroy cancerous tis-
sue. Chemotherapy treatment involves the use 
of drugs to hinder cancer growth or kill cancer 
cells [67]. A drug called 5-fluorouracil is the 
most common colorectal cancer chemotherapy 
treatment; it can be administered by a continu-
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ous pump, 48-hour infusion, weekly injections, 
or daily injections [65]. In radiation therapy, 
X-rays or other radiation methods are used to 
exterminate carcinogenic cells. Finally, the aim 
of targeted therapy is to use drugs, or other 
methods, to attack the specific cancer cells 
without damaging any other tissues [67].
Conclusions
Colorectal cancer is a deadly disease that 
afflicts and kills many, many people across the 
planet, mainly in the West; however, due to 
Western influences, colorectal cancer is on the 
rise in many Eastern nations as well. Research 
tells us that some dietary factors, namely high 
meat and animal-fat consumption, can pro-
mote colorectal carcinogenesis, whereas other 
dietary factors, such as fish, fiber, vitamin D, 
and calcium, can help prevent it. Research has 
also elucidated a genetic link to colorectal can-
cer, explaining that approximately 35% of risk is 
due to genes, and revealing how genes can 
confer both risks and protective effects. In 
addition, genetic factors and environmental 
factors jointly affect the risk of colorectal can-
cer. Though research constantly provides new 
information about effective screening meth-
ods, the dissemination and application of this 
knowledge is still lacking in many areas and 
amongst certain communities. Effective treat-
ment and prevention strategies have also been 
identified, tested, and documented. Research 
in these areas informs the public regarding how 
best to reduce their risk of developing colorec-
tal cancer, and because of the increasing 
5-year survival rate, provides reassurance that 
there are effective treatments in case they do 
develop this disease.
All the research found and presented here can 
provide a detailed, insightful, and informative 
look into the current situation regarding colorec-
tal cancer. Future public health efforts in this 
area should focus on increasing screening 
rates among African Americans as well as cre-
ating educational interventions for Eastern 
nations. With the increase in colorectal cancer 
cases in the East, it is evident that residents of 
these nations may be adopting the Western 
lifestyle without understanding its health con-
sequences. With that said, efforts should be 
made to increase health and nutrition educa-
tion, particularly regarding the effects of meat 
and animal fat. 
In addition, future efforts should be made to 
inform African Americans regarding the impor-
tance and benefit of undergoing colorectal 
screening by the age of 50 years, if not before. 
One possibly useful model might be the exam-
ple of President Reagan’s bout with colon can-
cer, an event that raised people’s awareness 
regarding this very issue. In the wake of Ronald 
Reagan’s fight with cancer, there was a rapid 
increase in the public’s interest in colorectal 
cancer, leading to increases in screening and a 
subsequent sharp decline in colorectal mortal-
ity beginning in 1985 [68, 69]. If someone who 
is trusted and influential in the African American 
community comes forward and speaks about 
the magnitude of this issue, positive changes 
are likely to follow.
Finally, future studies in colorectal cancer epi-
demiology should focus on the interaction 
between genetics and nutrients. Both genetic 
factors and certain foods may increase or 
decrease an individual’s likelihood of develop-
ing colorectal cancer. Thus, given a particular 
individual’s genetic makeup, future studies 
should aim to discover what foods (or other life-
style choices/behaviors) interact synergistical-
ly with that particular genotype to influence 
their colorectal cancer outcome. This would 
greatly increase our understanding of colorec-
tal cancer epidemiology while also providing 
the opportunity for much more specific and per-
sonalized treatment/prevention strategies.
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